Systemic Lupus Erthematosus
‘Complete eradication’ of B cells drives remission after autoimmune CAR T-cell therapy
A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment, according to a speaker.
Elsubrutinib, upadacitinib combination lowers lupus activity through 104 weeks
WASHINGTON — A drug combining elsubrutinib with upadacitinib led to lower disease activity for up to 104 weeks in patients with moderately to severely active systemic lupus erythematosus, according to data presented at ACR Convergence 2024.
Severe disease, strict endpoints in CAR T trials 'could be a way through the regulators'
SAN DIEGO — Regulatory trials of chimeric antigen receptor T-cell therapies for autoimmune diseases could be successful with a focus on patients with severe disease and strict endpoints, according to a speaker.
Dapirolizumab pegol achieves clinical improvement in moderate-to-severe lupus
Dapirolizumab pegol met its primary endpoint, achieving clinical improvement, when combined with standard-of-care treatment for moderate-to-severe systemic lupus erythematosus, according to topline results announced by its manufacturers.
Serology ‘significantly different’ between membranous vs. proliferative lupus nephritis
Proteinuria levels are not predictive of membranous lupus nephritis vs. proliferative lupus nephritis, according to data published in Rheumatology.
Attention, inhibitory control lower in patients with lupus vs general population
The ability to reason and solve new problems, known as fluid cognition, is lower among patients with systemic lupus erythematosus compared with the general population, according to data published in Arthritis Care & Research.